Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRRUS I: CFZ533 vs tacrolimus in de novo and maintenance kidney transplant recipients
jRCT2080224568Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, single-blind trial of iscalimab in kidney allograft rejection (2 arms), sponsored by Novartis. Started Feb 2019; status: completed.
02
Drugs
iscalimab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on jRCT2080224568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224568.